[Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration].
Comparison of the Pharmacokinetic Profiles of a Quick and a Sustained Release Bezafibrate Formulation/1st Communication: Single-dose application The hypolipaemic agent bezafibrate (CAS 41859-67-0) is available as immediate and sustained release formulation. The pharmacokinetic profile of an immediate release 300 mg dragee (A) was compared in a two-way cross-over design to that of a 400 mg sustained release dragee (B). Neglecting the dose difference, the AUEC of A (28.8 micrograms/ml.h) was equal to that of B (27.6 micrograms/ml.h), whereas the bioavailability of A appeared to be higher than that of B when AUEC was corrected for dose (AUEC ratio = 137%). Regarding Cmax and tmax, both formulations exhibited the expected differences.
Vens-Cappell
B
B
McKnight Laboratories GmbH, Hamburg.
Hilgenstock
C
C
Gellert
M
M
Kühle
K
K
Reifferscheid
I
I
Winckler
P
P
Bührens
K G
KG
D000328:Adult; D001629:Bezafibrate / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D003692:Delayed-Action Preparations; D004562:Electrocardiography; D006801:Humans; D008297:Male; D013607:Tablets
D003692:Delayed-Action Preparations; D013607:Tablets; D001629:Bezafibrate
Vergleich der Pharmakokinetik einer schnellfreisetzenden Bezafibrat-Formulierung mit einer Retard-Formulierung. 1. Mitteilung: Single-dose-Applikation.